Don’t miss – Page 157 – Endpoints News

SIGN UP

GSK, AstraZeneca plan to harness AI power for drug development from Nvidia's new, $50M-plus supercomputer now under construction

3 years ago

Harvard 'MacArthur genius’ Kevin Eggan steps in to run early-stage research at rare disease specialist BioMarin

3 years ago

Bristol Myers offers a big premium to reel in MyoKardia's cardio pipeline with a $13B buyout

3 years ago

Two top execs in Sanofi's R&D group are hitting the exit in a shakeup as Frank Nestle moves up to CSO

3 years ago

Pharma vet Valeria Fantin jumps to oncology team at Gilead; João Siffert out as Abeona looks for another CEO

3 years ago

Merck R&D chief Roger Perlmutter is handing off the big job to the exec in charge of discovery

3 years ago

FDA gives thumbs down for Mesoblast's aGVHD drug, saying one single-arm trial is not enough

3 years ago

Covid-19 roundup: AstraZeneca resumes vaccine trials in Japan; Global lab network is established to compare Covid-19 vaccines

3 years ago

AMAG tops its year-long, activist driven transformation with a $647M selloff to private equity

3 years ago

Is the future of diabetes drugs in dual GIP and GLP-1 incretin receptor agonists? That's the $47M question for Carmot

3 years ago

Roche shells out $200M for rights to Vaccibody's neoantigen cancer vaccine

3 years ago

Mesoblast asks for trading halt as PDUFA date slides by. What's up?

3 years ago

Solid gets another shot in DMD gene therapy race as FDA lifts hold. But is it too late to catch Pfizer, Sarepta?

3 years ago

Covid-19 roundup: EMA starts rolling review of AstraZeneca vaccine; Novavax execs sell millions in stock ahead of PhIII

3 years ago

Merck's Roger Perlmutter makes a rare move, joining the board of a machine learning startup out to change the R&D world. And he has some thoughts on that

3 years ago

The Endpoints 11: Here are some of the most promising startups in biotech. And Covid-19 isn't going to stop them

3 years ago

RNAi trailblazer Alnylam teases more positive data for a potential third commercial drug

3 years ago

A pharma exec gets $100M to chase a cancer-fighting idea uncovered in a 2017 Novartis study

3 years ago

Covid-19 roundup: Novartis' Vas Narasimhan sees drugs as 'bridge' to vaccines; Moderna spotlights elderly responses in NEJM

3 years ago

Regeneron offers a positive look at the first cut of its Covid-19 antibody cocktail — but just how well does it protect a vulnerable group?

3 years ago

Two years after Alex Denner activist attack, Ironwood plots mass layoffs as last clinical program goes up in smoke

3 years ago

Armed with a PhI cancer drug from Bayer, an Acerta founder breaks cover and writes himself a $60M blank check deal

3 years ago

Hooked by the science, Arie Belldegrun joins a group of influentials who believe Dewpoint may have the key to the next big thing in biotech

3 years ago

Covid-19 roundup: Researchers urge Pfizer to adopt high safety standard, hold vaccine EUA until late November

3 years ago

First page Previous page 154 155 156157158 159 160 Next page Last page